Strategic Partnerships C2N has active and growing collaborations with Mayo Clinic Laboratories, Grupo Fleury, Healius, Mediford, and international labs, plus partnerships with pharmaceutical and biotech companies and non-profits. Sales opportunity: leverage and expand distribution and co-development agreements with major labs and regional players to expand PrecivityAD adoption and unlock new geographies.

Global Expansion Existing partnerships span the US, Brazil, Australia, and other regions, indicating strong international demand for blood-based brain health tests. Sales opportunity: target additional international labs and hospital networks with a focus on CLIA-certified labs and CE-marked offerings to broaden accessibility and drive cross-border placements.

Product Evolution Introduction of PrecivityAD2 and expansion to use in patients 50 and older demonstrates an iterative product strategy to broaden addressable market. Sales opportunity: upsell and cross-sell enhanced panels or follow-on tests to existing customers and partner labs, plus pursue payer discussions for broader coverage as testing indications expand.

Clinical Adoption PrecivityAD is positioned as a supportive tool alongside clinical diagnosis, with FDA Breakthrough Device Designation and EU CE Mark. Sales opportunity: engage neurology clinics, memory care centers, and primary care networks through education and pilot programs to integrate blood-based brain health testing into standard diagnostic pathways.

Scale and Resources Strong revenue range and substantial funding, plus a focused R&D and lab certification base, indicate capacity to scale services and introduce new analytics or multi-analyte panels. Sales opportunity: explore value-based contracts with large health systems and offer tiered service levels for high-volume labs to accelerate onboarding and long-term adoption.